A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial.
BACKGROUND
Warfarin is effective in the treatment and prevention of many venous thromboembolic disorders, but it often leads to bleeding.


OBJECTIVE
To develop a multicomponent program of management of warfarin therapy and to determine its effect on the frequency of warfarin-related major bleeding in older patients.


METHODS
Randomized, controlled trial.


METHODS
University hospital in Cleveland, Ohio.


METHODS
325 patients 65 years of age or older who started warfarin therapy during hospitalization.


METHODS
Patients were stratified according to baseline risk for major bleeding and were randomly assigned to receive the intervention (n = 163) or usual care (n = 162) by their primary physicians for 6 months. The intervention consisted of patient education about warfarin, training to increase patient participation, self-monitoring of prothrombin time, and guideline-based management of warfarin dosing.


METHODS
Major bleeding, death, recurrent venous thromboembolism, and therapeutic control of anticoagulant therapy at 6 months.


RESULTS
In an intention-to-treat analysis, major bleeding was more common at 6 months in the usual care group than in the intervention group (cumulative incidence, 12% vs. 5.6%; P = 0.0498, log-rank test). The most frequent site of major bleeding in both groups was the gastrointestinal tract. Death and recurrent venous thromboembolism occurred with similar frequency in both groups at 6 months. Throughout 6 months, the proportion of total treatment time during which the international normalized ratio was within the therapeutic range was higher in the intervention group than in the usual care group (56% vs. 32%; P < 0.001). After 6 months, major bleeding occurred with similar frequencies in the intervention and usual care groups.


CONCLUSIONS
A multicomponent comprehensive program of warfarin management reduced the frequency of major bleeding in older patients. Although the generalizability and cost-effectiveness of this program remain to be demonstrated, these findings support the premise that efforts to reduce the likelihood of major bleeding will lead to safe and effective use of warfarin therapy in older patients.
Beyth
R J
RJ
Baylor College of Medicine, Section of Health Services Research, Houston Center for Quality of Care and Utilization Studies, Veterans Affairs Medical Center (152), Building 110T, 2002 Holcombe Boulevard, Houston, TX 77030, USA. rbeyth@bcm.tmc.edu
Quinn
L
L
Landefeld
C S
CS
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D004311:Double-Blind Method; D016903:Drug Monitoring; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010347:Patient Care Planning; D010353:Patient Education as Topic; D011517:Prothrombin Time; D012008:Recurrence; D012648:Self Care; D020246:Venous Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D014859:Warfarin